BANK VONTOBEL/CALL/BIOGEN IDEC/250/0.01/21.06.24 | Market Closed - Deutsche Boerse AG 11:33:20 31/05/2024 pm IST | ||
| 0.01 EUR | +100.00% |
|
| 3 months | -77.27% | ||
| 6 months | -94.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 0.01 | +100.00% |
| 30/24/30 | 0.005 | +150.00% |
| 29/24/29 | 0.002 | -50.00% |
| 28/24/28 | 0.004 | +33.33% |
| 27/24/27 | 0.003 | -25.00% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 11:33 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VM2M59 |
| ISIN | DE000VM2M597 |
| Date issued | 18/09/2023 |
| Strike | 250 $ |
| Maturity | 21/06/2024 (20 Days) |
| Parity | 100 : 1 |
| Emission price | 0.3 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.46 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.011 € |
| Spread % | 55.00% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
224.9
USD
Average target price
284.8
USD
Spread / Average Target
+26.60%
- Stock Market
- Warrants
- Warrant
